Role of Low-Field Portable MRI in Small Vessel Disease Identification

Adam de Havenon1,2, Matthew J Huentelmen3

  • 1Department of Neurology (A.d.H.), Yale University, New Haven, CT.

Stroke
|July 21, 2026
PubMed

Insights

Portable MRI shows promise for detecting cerebral small vessel disease (SVD) biomarkers, similar to conventional MRI. This technology could improve early detection and access to brain health assessments for age-related SVD.

Area of Science:

  • Neurology
  • Radiology
  • Biomedical Engineering

Background:

  • Cerebral small vessel disease (SVD) is a prevalent age-related brain pathology.
  • Conventional high-field MRI is the standard for SVD biomarker detection but has limitations in accessibility and early detection.
  • Low-field portable MRI offers point-of-care capabilities with reduced infrastructure needs.

Purpose of the Study:

  • To review emerging evidence on the utility of low-field portable MRI for detecting SVD features.
  • To highlight the potential of portable MRI in overcoming limitations of conventional MRI for SVD assessment.
  • To focus on the detection of white matter hyperintensity using portable MRI.

Main Methods:

  • Review of existing literature and emerging evidence on portable MRI for SVD detection.
  • Comparison of findings from low-field portable MRI with conventional MRI standards.
  • Emphasis on specific SVD biomarkers, particularly white matter hyperintensity.

Main Results:

  • Portable MRI systems (<0.1T) demonstrate concordance with conventional MRI for detecting various SVD features.
  • Emerging evidence supports the use of portable MRI for identifying key SVD biomarkers.
  • White matter hyperintensity is a primary focus for portable MRI-based SVD assessment.

Conclusions:

  • Low-field portable MRI is a promising tool for detecting cerebral small vessel disease biomarkers.
  • Future research should focus on longitudinal validation and integration into clinical trials for SVD.
  • Portable MRI can potentially enhance early identification, monitoring, and equitable access to brain health evaluations for SVD.